Prime Therapeutics Launches MedDrive for Greater Biosimilar Drug Adoption

 Prime Therapeutics Launches MedDrive for Greater Biosimilar Drug Adoption

Shots:

  • Prime Therapeutics launches MedDrive in multiple phases and provide a solution to help Blue Plan clients for greater biosimilar adoption and drug cost-saving strategies
  • Prime helps the Blue Plan clients through a 100% transparent, unbiased PBM model that serves nearly 33M members across 23 Blue Plans
  • Prime and Blue Cross plans to improve the use of biosimilars and other lower cost for effective treatment and to deliver improved affordability without compromising patient outcomes

Click here to­ read full press release/ article | Ref: Prime Therapeutics | Image: Prime Therapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post